Impact investments in outstanding healthcare projects
Article25: Right to an adequate standard of living
Everyone has the right to a standard of living adequate for the health and well-being of him/herself...
The Universal Declaration of Human Rights
United Nations. December 10, 1948
in areas with clear clinical or health related unmet needs, to make a significant contribution...
to create a synergistic effect in the investment field of leveraged contributions to make a...
of exit scenarios to guarantee an expedited fruitful divestment
Meaningful investments in areas of unmet need in healhcare, coordinated to make a substantial social impact within a predefined time frame.
80%
fund capital Flagship GrowthIndustrial and healthcare infrastructure, risk-mitigated impactment investment projects
20%
fund capital BreakthroughTransformational investments in innovative projects in lifesciences, biotech and technology
Innovative and dynamic professional with +20 years of technical, entrepreneurial and leadership experience in Molecular Diagnostics and Precision Medicine.
Recent work focused on strategic advice to major global pharmaceutical and Dx companies, Investment Funds, VCs, and Governments on precision medicine strategies and on the effective integration of Dx and Rx into drug development and market adoption pathways. European Commission advisor. ASCO evaluator.
MD, PhD, MBA. Spare time devoted to collaborations with NGOs, having founded children’s NGOs in Africa and Europe. Enjoys travelling, cultural activities, music, arts, horseback riding, yoga, squash and tennis.
Strategic Advisor
Innovation leader with over 50 years of management experience in the electronics industry, having also multiple successful entrepreneur, investor and executive experiences as chairman (MIMS, RAMTRON, Reaction Design), CEO (AMCC, GGTI), board member (iBOSS, NetClearance Systems, HVVI, Mobileworks.com, MCHP, ONNN, AMKOR), COO (Burr Brown Research), and advisor (Don Valentin, Sequolia Partner, Founder and John Prior, Needham @Co).
MSEE, MBA.
Strategic Advisor
Strategic Advisor
Economist with extensive experience in strategic consulting (PWC, Accenture, E&Y, Everis), having held the position of Senior Partner and Global Director of the Digital Strategy Unit, and Senior Partner Public Sector & Global Health of Everis, and a member of its Global Management and Human Resources committees.
PAD.
Strategic Advisor
Advisor
Ex CEO of several NASDAQ Dx companies.
Managing director of VC Fund.
Advisor
Medical Advisor
Medical Oncologist with over 30 years of scientific, clinical and patient experience including as Principal Investigator on several studies at MD Anderson Cancer Center and as Director of the International Patient Center and having served as board member and advisor to several biotechs and start ups in the Oncology and Diagnostics field in the US and Latam (Millenium Lymphoma, Celgene...).
MD, PA.
Medical Advisor
Strategic Advisor
Diagnostics and therapeutics mentor at the Wyss Institute, having over 35 years of experience in the medical device and pharmaceutical fields, focusing on innovation for companies such as Imclone Systems, BD, Roche Diagnostics, Johnson and Johnson and Novartis, as well as starting his own management consulting firm focused on the performance of due diligence and transactions.
Regards himself as a generalist who is able to integrate innovative science in the context of healthcare systems as complex business ecosystems with multiple stakeholders.
PhD.
Strategic Advisor
There were several highlights in May about new approvals for targeted treatments, deals for companion diagnostics and updates on drug development. May 26 was the due-date for in vitro medical devices to meet criteria of the new European IVD regulation. A day circled in red by diagnostic companies undergoing product certification, since low-risk IVDs have been postponed depending on class risk:...
This spring opened with a number of compelling progresses in the adoption of diagnostics, especially in Europe.
Genetron Health obtained CE Mark for its Seq-MRD for patients with B lymphocytic leukemia and multiple myeloma before and after treatment. Lunit obtained CE mark for its Lunit Scope PD-L1 TPS, an AI-based test to analyze PD-L1 expression in both tumor and inflammatory cells from...
This month confirms a focus of companies and institutions on precision medicine to advance patients' testing and treatments, with more and more opportunities made available throughout the entire globe.
The Spanish Societies of Oncology and Pathology issued an official claim to the NHS for the coverage of biomarker testing and to establish reference centers for NGS in the National territory....
This February witnessed an update for the EU Parliament for the Fight Against Cancer Plan, several collaborations for CDx developments, as well as new Dx launches, especially for IVD tests for early-stage cancer.
AmoyDx partnered with Pierre Fabre to develop a CDx in China to detect BRAF mutation in tumor samples and select patients eligible for Braftovi (encorafenib) with or without Mektovi...
This year’s opening was flagged by several announcements on clinical application of advanced tools for molecular diagnostics as well as new deals for precision oncology.
The JP Morgan Healthcare Conference showcased major healthcare companies and their strategic plans foreseen for 2022. Illumina introduced Chemistry X, a new breakthrough technology advancing current sequencing status, and...
There is no doubt that in 2021 precision oncology made huge steps forward on the promise of targeted treatment, both on biomarkers as well on new therapies, especially in lung and breast cancer, with CRC as an emerging indication.
Indeed, one of the most remarkable breakthrough of the year are KRAS G12C inhibitors for NSCLC, along with different strategies to select patients by both tissue or...
The closing of 2021 brought outstanding news on the accessibility of predictive diagnostics in Europe with key government decisions taken by two Member States.
In Spain, National Healthcare will incorporate predictive genetic analysis with public funding in the healthcare portfolio of common specialized care services, while Italy will establish regional Molecular Tumor Boards (MTBs) allowing...
In this late fall the development of advanced diagnostics tests is fueled by new companies' partnerships, regulatory approvals and public funding worldwide.
In the liquid biopsy space, Burning Rock and Merck KGaA entered a CDx agreement for the MET inhibitor tepotinib in the Chinese market with the OncoCompass Target. AstraZeneca started a strategic collaboration with Saga Diagnostics to...
October was pivotal month for biomarker testing landscape, especially for EU countries due to the updates on the implementation of the upcoming IVDR, extending the transition phase to cancer diagnosis IVD products, delaying 1 to 3 years depending on the product.
ESMO updated clinical practice guidelines for metastatic breast cancer. Patients with TNBC tumor should get PD-L1 testing and...
September is a month with important milestones presented during ESMO and WCLC. Outstanding results from DESTINY trials paved the way for new therapeutic options and clinical standards based on Daiichi-Sankio’s conjugated MoAb ENHERTHU (trastuzumab-deruxtecan) for patients with lung, gastric and breast cancer. Impressive clinical outcomes also by IMFINZI in NSCLC (plus I/O) and in SCLC....
Inflection Point Biomedical Advisors (IPBA) provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to EU and US governmental agencies.
IPBA is a key collaborator and vital partner of Article25 Impact Ventures
